Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  polifeprosan 20 with carmustine implant
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
Phase III Randomized Evaluation Of Convection Enhanced Delivery Of IL13-PE38QQR (Interleukin-13 PE38QQR Immunotoxin) Compared To Gliadel® Wafer (Polifeprosan 20 With Carmustine Implant) In Glioblastoma Multiforme Patients At First Recurrence
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NEOPHARM-IL13PEI-301, UCLA-040305101, NEOPHARM-IL13PEI-301-R01, PRECISE, NCT00076986
Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 64
Sponsor: Pharmaceutical / Industry
Protocol IDs: NPC-08-1, NCT00919737
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: 12BN101, NCT02085304
Phase II Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Patients With Supratentorial Brain Metastases Undergoing Surgical Resection
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9802, JHOC-NABTT-9802, NCT00003878
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: Pro00004127, DUMC-5515-06-1R2, DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, CDR0000483768, NCT00362921
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GLIA-001, NCT00525590
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1706, DUMC-1706-02-9R5, DUMC-1706-01-9R4, DUMC-000693-00-4, DUMC-1509-97-10, DUMC-1568-98-10R1, DUMC-1706-00-9R3, DUMC-97131, NCI-G98-1470, CDR0000066503, NCT00003467
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00025180, NCT01186406
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000696316, CRUK-UCL-09-0398, 2010-022496-66, 09/0398, 10/H0304/100, UCL/09/0398 v2.0, GALA-5, EUDRACT-2010-022496-66, NCT01310868
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 0901, DUMC-0901-02-5R4, DUMC-0901-02-5R2, DUMC-000901-00-5R2, DUMC-000901-01-5R3, DUMC-0797-99-5RI, DUMC-796-98-5, DUMC-98065, UCLA-9812060, NCI-G98-1464, DUMC-0901-01-5R3, CDR0000066497, NCT00003463
Phase I Study of Polifeprosan 20 with Carmustine Implant (Gliadel Wafers) in Children and Adolescents with Recurrent Supratentorial Glial Tumors (Summary Last Modified 11/1999)
Phase: Phase I
Type: Treatment
Status: Closed
Age: Under 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: RP-RPR132596-150MA, NCI-V98-1465
Phase I Study of Polifeprosan 20 With Carmustine Implants (Gliadel Wafers) and O6-Benzylguanine in Patients With Recurrent Malignant Glioma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9803, JHOC-NABTT-9803, NCT00004892
Start Over